AOD-9604 is a synthetic 16-amino-acid peptide fragment corresponding to the C-terminal region (amino acids 176-191) of human growth hormone, with an added N-terminal tyrosine. It selectively activates beta-3 adrenergic receptors to stimulate fat metabolism without engaging the GH receptor, producing no effect on IGF-1, glucose, or growth signalling.

How does AOD-9604 work for fat loss?

AOD-9604 binds beta-3 adrenergic receptors on adipocytes, activating hormone-sensitive lipase to break down stored triglycerides. Unlike full-length GH, it does not raise IGF-1 or cause insulin resistance. However, its pivotal Phase IIb obesity trial (536 participants) failed to demonstrate weight loss and was terminated in 2007.

What is the correct AOD-9604 dose?

The standard subcutaneous dose is 250 mcg once daily, administered in the morning after an 8-10 hour fast. Advanced protocols use 300-500 mcg. The compound must be taken fasted because insulin blocks its mechanism of action at the adipocyte level. Typical cycles are 30-90 days followed by a 4-week rest.

In clinical trials, AOD-9604 showed a mild side effect profile: injection site reactions, occasional headaches, and GI distress at high oral doses. It does not raise IGF-1 or disrupt glucose. However, no human safety data exists beyond 24 weeks, grey market products carry contamination risks, and the FDA removed it from its Category 2 bulk drug list in April 2026.

Is AOD-9604 FDA approved?

No. AOD-9604 has never been approved as a drug in any jurisdiction. In April 2026, the FDA removed it from the Category 2 bulk drug substances list, effectively closing the 503A compounding pathway. It has no USP/NF monograph and no approved drug precedent. It is also banned by WADA.

Does AOD-9604 help with joint repair?

Preclinical data from a 2015 rabbit osteoarthritis model showed that intra-articular AOD-9604 combined with hyaluronic acid enhanced cartilage regeneration. However, this was tested in 32 rabbits with no human follow-up. The intra-articular route bypasses the peptide's 3-4 minute plasma half-life. Whether subcutaneous dosing provides any joint benefit is unknown.

How does AOD-9604 compare to GLP-1 drugs like semaglutide?

They are fundamentally different. Semaglutide (Ozempic/Wegovy) has robust Phase III data showing 15-20% body weight reduction, FDA approval, and a well-characterised safety profile. AOD-9604 failed its Phase IIb trial and has no approved indication. There is zero clinical data on combining them.

Why do I need to fast before taking AOD-9604?

AOD-9604 works by activating beta-3 adrenergic receptors on fat cells. Insulin, which rises after eating, directly opposes this mechanism by suppressing hormone-sensitive lipase and downregulating B3-AR expression. Without a proper fast (8-10 hours minimum), the compound cannot effectively drive lipolysis. The fasting requirement is mechanistic, not optional.

AOD-9604: Peptide Profile & Protocol

AOD-9604 is not a naturally occurring peptide. It is a synthetic 16-amino-acid fragment corresponding to the C-terminal region of human growth hormone (amino acids 176-191), with an added N-terminal tyrosine residue that stabilises the molecule and enhances receptor binding.

How It Works

The fragment selectively targets beta-3 adrenergic receptors (B3-AR) on adipocytes, activating hormone-sensitive lipase to break down stored triglycerides. Critically, AOD-9604 does not bind or activate the GH receptor. This means no downstream IGF-1 elevation, no glucose perturbation, and no proliferative signalling, the side effects that make full-length GH problematic for long-term use.

Pharmacokinetics

Plasma half-life: approximately 3-4 minutes (extremely short).
Route: subcutaneous injection (primary), oral (historical trials), intra-articular (preclinical).
Clearance: rapid enzymatic degradation typical of small peptide fragments.
Systemic exposure: minimal, raising questions about whether the compound reaches target tissue in meaningful concentrations after subcutaneous dosing.

The Key Distinction

Unlike full-length growth hormone or secretagogues like MK-677, AOD-9604 isolates the lipolytic signal from the growth signal. There is no IGF-1 increase, no insulin resistance, no fluid retention, and no proliferative risk. The trade-off is a compound with an extraordinarily short plasma half-life that may limit its systemic reach.

The defining event in AOD-9604's clinical history is the Phase IIb OPTIONS study: a multicentre, randomised, double-blind trial enrolling 536 obese participants (BMI 35-45) across multiple dose arms.

What Happened

The trial was designed to demonstrate dose-dependent weight loss over 24 weeks. Instead, the placebo arm lost more weight than anticipated, collapsing the statistical separation between treatment and control groups. The trial was terminated in 2007 without achieving its primary endpoint.

Why It Matters

No peer-reviewed publication: the Phase IIb failure was never published in a peer-reviewed journal. The data exists only in regulatory filings and secondary analyses.
Earlier positive signal: a smaller 12-week trial had shown statistically significant weight loss versus placebo, but the larger confirmatory trial did not replicate it.
Placebo dynamics: the study population (BMI 35-45) was highly responsive to the behavioural components of trial participation: dietary counselling, regular weigh-ins, and clinical attention.

The Pattern

AOD-9604 joins a long list of obesity drug candidates that cleared early-phase trials but could not survive the placebo response in larger, longer studies. The biological mechanism may be real, but the clinical signal was too small to separate from the noise of structured lifestyle intervention.

AOD-9604 requires a minimum 8-10 hour fast before administration. This is not a convenience recommendation; it is a mechanistic requirement rooted in how the compound interacts with the metabolic environment.

The Insulin Problem

Insulin and beta-3 adrenergic signalling are functionally opposed at the adipocyte level. Insulin activates lipogenesis (fat storage) and suppresses hormone-sensitive lipase (fat breakdown). AOD-9604 activates fat breakdown via B3-AR. When both signals are present simultaneously, the result is a metabolic stalemate: the compound cannot drive lipolysis because insulin is actively blocking the downstream enzyme.

B3-AR Upregulation

Fasting state: low insulin allows B3-AR expression to increase on adipocyte surfaces, amplifying AOD-9604's target availability.
Fed state: elevated insulin downregulates B3-AR density, reducing the number of receptors available for the peptide to bind.
Practical window: dosing in the morning after overnight fast provides the optimal low-insulin environment. Wait 30-60 minutes before eating after injection.

Clinical Implications

Users who administer AOD-9604 without proper fasting are likely receiving minimal benefit. The compound's mechanism depends entirely on the metabolic context of administration. This makes adherence to the fasting protocol as important as the dose itself.

After the obesity programme collapsed, researchers redirected AOD-9604 toward an unexpected application: cartilage and joint repair. The preclinical data, while limited to animal models, represents the compound's most intriguing current research direction.

The Rabbit OA Model (2015)

In a 2015 study using a surgically induced osteoarthritis model in 32 rabbits, ultrasound-guided intra-articular injections of AOD-9604 combined with hyaluronic acid (HA) demonstrated enhanced cartilage regeneration compared to HA alone. The combination showed improved cartilage surface integrity, reduced degradation markers, and evidence of chondrocyte proliferation.

What the Data Shows

Administration: ultrasound-guided intra-articular injection directly into the joint space.
Combination: AOD-9604 + hyaluronic acid outperformed HA alone.
Mechanism: the peptide fragment appears to stimulate chondrocyte activity through a pathway distinct from its lipolytic B3-AR mechanism.
Limitation: 32 rabbits. No human joint repair trial exists.

The Translation Problem

Rabbit cartilage biology differs substantially from human cartilage biology. Rabbits have greater intrinsic cartilage repair capacity. The intra-articular route bypasses the 3-4 minute plasma half-life problem entirely by delivering the compound directly to the target tissue. Whether systemic (subcutaneous) dosing produces any meaningful joint benefit is unknown and mechanistically doubtful.

AOD-9604's regulatory position has deteriorated significantly and continues to narrow.

Current Status (as of April 2026)

FDA Category 2 removal: in April 2026, the FDA removed AOD-9604 from its Category 2 bulk drug substances list. This effectively closes the compounding pathway under Section 503A.
No USP/NF monograph: AOD-9604 has no United States Pharmacopeia or National Formulary monograph, a prerequisite for standard compounding eligibility.
No approved drug precedent: the compound was never approved as a drug in any jurisdiction, which eliminates the approved-drug pathway for compounding.
WADA prohibited: AOD-9604 is banned under the World Anti-Doping Agency prohibited list (peptide hormones and growth factors category).

What This Means

The FDA's Category 2 removal is a regulatory signal that the risk-benefit profile does not support compounding. Compounding pharmacies that previously offered AOD-9604 under 503A are no longer on solid regulatory ground. Products available through grey market channels lack any manufacturing quality standards, purity verification, or regulatory oversight.

The Sourcing Reality

Any AOD-9604 product currently available for human use exists outside the regulated pharmaceutical supply chain. This introduces contamination risk, dosing inaccuracy, and the possibility of degraded or substituted product. The compound's extremely short half-life makes it particularly sensitive to handling and storage conditions.

AOD-9604 is surrounded by marketing claims that outpace its evidence base. Here is what holds up and what does not.

Supported by Evidence

Selective lipolytic mechanism: AOD-9604 activates B3-AR without GH receptor engagement. No IGF-1 elevation, no glucose disruption. This is confirmed in human pharmacokinetic data.
Mild side effect profile: across clinical trials, adverse events were limited to injection site reactions, mild headaches, and occasional GI distress at high oral doses. No serious systemic toxicity was identified.
Preclinical cartilage signal: the rabbit OA model showed genuine cartilage regeneration enhancement with intra-articular AOD-9604 + HA.

Not Supported by Evidence

Weight loss in humans: the pivotal Phase IIb trial failed. No large human study has demonstrated clinically significant weight loss.
Joint repair in humans: zero human clinical data exists for cartilage or joint repair. The data is from 32 rabbits.
Systemic joint benefit: the cartilage data used intra-articular injection. Subcutaneous dosing for joint health has no mechanistic or clinical support.
Compounding availability: the FDA Category 2 removal effectively closes the legal compounding pathway.

The Honest Assessment

AOD-9604 is a compound with an elegant mechanism, a clean safety profile, and no confirmed clinical efficacy in humans for any indication. Its biological potential has never translated to commercial success. The most honest question is not whether it works for fat loss, but whether its cartilage repair signal can survive the leap from rabbit knees to human joints.

AOD-9604 represents a precise piece of molecular engineering: a GH fragment that activates fat metabolism without the side effects of growth hormone. But precision of mechanism has not translated to proof of efficacy. The obesity programme failed, the regulatory window has closed, and the most promising research direction (cartilage repair) rests on 32 rabbits. The compound's story is a case study in the gap between biological plausibility and clinical proof, and a provocation about whether its future lies in joints rather than fat.

1.Molecular Engineering: A Fragment with a Selective Target

How It Works

Pharmacokinetics

The Key Distinction

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Related Research

Fat Loss: Lipolysis

Appetite Suppression

Muscle Growth: Hypertrophy

Injury Repair: Tendons / Ligaments

Bone Density

Increased Strength

Stay Ahead of the Research

2.The OPTIONS Trial: When Placebo Wins